Omnicell, Inc. (OMCL) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a positive outlook with increased revenue and EPS guidance, improved margins, and strategic investments in product development and market expansion. The Q&A section highlights strong competitive positioning and confidence in new product launches. Although there are some uncertainties, such as the impact of tariff costs and the timeline for new product adoption, the company's proactive strategies and optimistic guidance suggest a positive sentiment. Given the market cap of approximately $1.2 billion, the stock is likely to see a positive reaction, between 2% and 8%, over the next two weeks.
Key Financial Performance
Total Revenue (Q4 2025) $314 million, an increase of 2% year-over-year. The increase was driven by strong demand for connected devices and improved customer scheduling and coordination.
Product Revenue (Q4 2025) $180 million, a decrease of 1% year-over-year. The decline was attributed to shifts in product and customer mix.
Service Revenue (Q4 2025) $134 million, an increase of 8% year-over-year. The growth was driven by improvements in service margins and software upgrades for customers.
Non-GAAP Gross Margin (Q4 2025) 43.2%, down from 47.4% in Q4 2024. The decline was due to $7 million in tariff costs and shifts in product and customer mix.
GAAP Earnings Per Share (Q4 2025) Loss of $0.05 per share, compared to a profit of $0.34 per share in Q4 2024. The loss was influenced by tariff costs and increased operating expenses.
Non-GAAP Earnings Per Share (Q4 2025) $0.40, down from $0.60 in Q4 2024. The decrease was due to higher operating expenses and tariff costs.
Non-GAAP EBITDA (Q4 2025) $37 million, down from $46 million in Q4 2024. The decline was attributed to increased operating expenses and tariff costs.
Cash and Cash Equivalents (End of 2025) $197 million, down from $369 million at the end of 2024. The decrease was due to debt repayment of $175 million and $78 million in stock repurchases.
Free Cash Flow (Q4 2025) $18 million, down from $43 million in Q4 2024. The decline was due to increased operating expenses and tariff costs.
Annual Recurring Revenue (ARR, End of 2025) $636 million, an increase of 10% year-over-year. The growth was driven by strong demand for cloud-based offerings and software subscriptions.
Total Revenue (Full Year 2025) $1.185 billion, up from $1.112 billion in 2024. The increase was driven by strong demand for connected devices and service revenue growth.
Product Revenue (Full Year 2025) $666 million, up from $631 million in 2024. The growth was driven by strong demand for connected devices.
Service Revenue (Full Year 2025) $519 million, up from $482 million in 2024. The increase was driven by improvements in service margins and software upgrades for customers.
Non-GAAP Earnings Per Share (Full Year 2025) $1.62, down from $1.71 in 2024. The decline was due to reduced interest income and increased operating expenses.
Non-GAAP EBITDA (Full Year 2025) $140 million, up from $136 million in 2024. The increase was driven by strong demand for connected devices and service revenue growth.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Titan XT launch: Introduced at the ASHP Annual Meeting in December 2025, Titan XT is a transformational enterprise-wide automation dispensing system designed to unify automation and intelligence for efficient medication management.
OmniSphere platform: Cloud-based platform designed to unify all Omnicell products under a single infrastructure, providing enterprise-wide visibility into medications and supply inventory. Achieved HITRUST CSF i1 certification in 2025.
Market expansion: Omnicell is growing its product footprint across inpatient and outpatient care environments, including nursing units, operating rooms, and pharmacy settings. Recent wins include health systems in Louisiana, Mississippi, Texas, New England, Western New York, Honolulu, and Canada.
Government partnerships: The Department of Veteran Affairs selected Omnicell's point-of-care dispensing and IV workflow solutions for medication management across its hospital network.
Recurring revenue growth: Annual recurring revenue (ARR) reached $636 million in 2025, a 10% increase from 2024.
Revenue performance: Total revenue for 2025 was $1.185 billion, with product revenue at $666 million and service revenue at $519 million.
Focus on autonomous medication management: Omnicell is advancing its transformation into an end-to-end medication management platform technology company, emphasizing innovation and customer-centric solutions.
Investment in technology and customer experience: Investments in Titan XT, OmniSphere, and back-office systems, including a $10 million ERP system update in 2026, aim to enhance operational efficiency and customer satisfaction.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Environment and Tariffs: The company faces potential uncertainty around regulations and tariffs, which could impact financial performance. Tariff costs in 2025 amounted to $7 million, and the guidance for 2026 includes an estimated $15 million in tariff costs. The fluidity of the regulatory environment adds to the risk.
Non-GAAP Gross Margin Decline: Non-GAAP gross margins declined by approximately 4 percentage points in Q4 2025 compared to Q4 2024, primarily due to $7 million in tariff costs and shifts in product and customer mix. This decline could affect profitability.
Debt Repayment and Cash Reserves: The company’s cash and cash equivalents decreased significantly from $369 million in 2024 to $197 million in 2025, primarily due to the repayment of $175 million in debt and $78 million in stock repurchases. This reduction in cash reserves could limit financial flexibility.
Product Lifecycle Transition: The transition from XT hardware to Titan XT hardware may create near-term headwinds as customers adjust their capital budget approval cycles. The replacement cycle opportunity is estimated at $2.5 billion, but the pacing of product bookings and revenue could be slower than expected.
ERP System Transformation Costs: The company plans to invest approximately $10 million in 2026 to update and refresh its enterprise resource planning (ERP) systems, which are coming off vendor support in 2027. This represents a significant operational cost.
Seasonal and Operational Expenses: Seasonally higher expenses, including payroll taxes and benefits reset, are expected in Q1 2026. Additionally, costs associated with the American Society of Hospital Pharmacists Annual Meeting and investments in customer experience and human capital initiatives increased operating expenses in Q4 2025.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Projections for Q1 2026: Total revenue is expected to be between $300 million and $310 million, with product revenue anticipated to be between $171 million and $176 million, and service revenue expected to be between $129 million and $134 million.
Revenue Projections for Full Year 2026: Total revenue is expected to be in the range of $1.215 billion to $1.255 billion. Product revenue is expected to be in the range of $690 million to $710 million, and service revenue is expected to be in the range of $525 million to $545 million.
Annual Recurring Revenue (ARR) for 2026: Year-end 2026 ARR is expected to be in the range of $680 million to $700 million.
Non-GAAP EBITDA for 2026: Non-GAAP EBITDA for the full year 2026 is expected to be in the range of $145 million to $160 million.
Non-GAAP Earnings Per Share for 2026: Non-GAAP earnings per share is expected to be in the range of $1.65 to $1.85 per share.
Product Bookings for 2026: Full year 2026 product bookings are anticipated to be in the range of $510 million to $560 million.
Tariff Costs Impact in 2026: Guidance includes an estimated tariff cost of approximately $15 million for 2026.
Titan XT and OmniSphere Platform Launch: Titan XT is expected to be available for shipment in the second half of 2026, while improved software functionality in OmniSphere is anticipated in the first half of 2027.
ERP System Update Costs: Approximately $10 million of expenses in 2026 are allocated for the transformation and refresh of enterprise resource planning (ERP) systems.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Repurchase of common stock: The company repurchased approximately $78 million of its common stock during 2025.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the expectations for the Titan cycle and its ramp over the next few years?
A:The Titan cycle is expected to follow a typical 8- to 10-year replacement cycle, similar to the XT refresh. The refresh cycle is estimated to be in excess of $2.5 billion, with a similar level of rollout over the next 8 years. The focus is on the platform's capabilities rather than just hardware upgrades, and there is significant excitement and momentum in the market.
Q:Will there be incremental investments in sales force, clinical education, marketing, and support for the Titan cycle?
A:Yes, the company is making investments in the sales force, clinical education, and marketing to capitalize on the market opportunity. These investments are aimed at ensuring customers understand the value of the new solutions and to remain competitive in the market.
Q:What is the feedback from customers who signed contracts for XTExtend regarding the launch of Titan?
A:Customers who invested in XTExtend can still access cloud capabilities through OmniSphere, as XTExtend consoles are cloud-enabled. The company is meeting customers where they are, providing paths to the cloud for all customers.
Q:What are the plans to mitigate tariff costs and improve gross margins?
A:The company is implementing mitigation efforts to address tariff costs, which are expected to be $15 million in 2026. These efforts include optimizing the global supply chain network to reduce costs and improve margins. The impact of tariffs is expected to be more front-end weighted in 2026.
Q:What is the competitive environment and the company's strategy for gaining market share?
A:The company is seeing strong momentum and is engaging in more competitive conversations due to the timing of the Titan launch. The focus is on leveraging the reliability and innovation of their products to gain market share. The guidance assumes a modest step-up in bookings, reflecting confidence in their competitive positioning.
Q:What is the impact of OmniSphere on margins and the go-to-market strategy?
A:OmniSphere is expected to drive recurring revenue and improve margins. The company is pressure testing the product with customers and plans to provide a comprehensive review in the second half of the year. The focus is on accelerating adoption of OmniSphere and leveraging its capabilities to generate new revenue streams.
Q:What are the growth drivers for ARR and expectations for 2026?
A:ARR growth is driven by technical services, consumables, and specialty businesses. The company had a strong performance in 2025 and expects these factors to continue driving growth in 2026.
Q:How does the company address the lease structure of competitors' ADC installed base?
A:The company has introduced an Omnicell-driven financing program to remain competitive in bid situations. This program allows the company to stay in conversations longer and potentially gain additional customers.
Q:What is the company's view on AI tools and their impact on OmniSphere?
A:The company views AI as a net positive, as it requires an enterprise-wide infrastructure to operate effectively. OmniSphere provides the necessary infrastructure for AI tools, making it a valuable platform for customers.
Q:What is the update on robotics and its contribution to revenue?
A:Robotics is not a material component of revenue currently, but the company believes automation and robotics are part of the solution to health system challenges. They are working on the right suite of solutions to meet market needs.
Q:What is the update on Enliven and 340B services?
A:Enliven is facing headwinds in the retail segment, but the company believes in the long-term value of its solutions. The 340B program is a compelling part of the specialty business, and the company does not expect material changes to revenue expectations despite market chatter.
Q:What are the expectations for the ERP platform implementation?
A:The ERP platform implementation will be a multiyear effort, with expected efficiencies and benefits to the business. The company plans to use the system to improve customer interactions and commercial opportunities.
Q:What is the expected adoption cycle for Titan?
A:The Titan adoption cycle is expected to follow a bell curve, with peak adoption in years 3 to 5. However, the company plans to introduce additional products on the OmniSphere platform to create a more sustainable and recurring revenue model.
Q:What is the company's strategy for competitive conversions during the Titan cycle?
A:The company believes it is well-positioned to gain market share due to the complexity of customer needs and the capabilities of its platform. The focus is on providing enterprise-level solutions that resonate with large, complex organizations.
Q:What is the company's approach to hosting data for OmniSphere and Titan?
A:Omnicell will host the data for OmniSphere and Titan, providing secure, real-time access and eliminating the need for customers to manage on-premise equipment. This approach supports the company's recurring revenue model.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the following:
1. The exact timeline for the adoption of OmniSphere and its impact on margins.
2. The specific contribution of robotics to revenue and its future potential.
3. The detailed impact of the ERP platform implementation on margins and efficiencies.
4. The exact timing for when XT will no longer be supported and the transition to Titan will be mandatory.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ARR midpoint
ASHP Annual
Affairs point
Annual Meeting
British Columbia
CEO finish
Canada health
Columbia Vancouver
Department Veteran
England health
Full Financial
HITRUST medication
Hawaii provider
Healthcare Technology
Honolulu
New
OmniSphere
Radford
Titan XT
XTExtend
automation intelligence
care dispensing
commitment
cost
health care
market presence
medication inventory
medication platform
network
patient outcome
point care
power
staff efficiency
strength
technology platform
term value
OMCL Transcript
Omnicell, Inc. (OMCL) Q4 2025 Earnings Call Transcript
Positive2-5
The earnings call reveals a positive outlook with increased revenue and EPS guidance, improved margins, and strategic investments in product development and market expansion. The Q&A section highlights strong competitive positioning and confidence in new product launches. Although there are some uncertainties, such as the impact of tariff costs and the timeline for new product adoption, the company's proactive strategies and optimistic guidance suggest a positive sentiment. Given the market cap of approximately $1.2 billion, the stock is likely to see a positive reaction, between 2% and 8%, over the next two weeks.
Omnicell, Inc. (OMCL) Q3 2025 Earnings Call Transcript
Positive10-30
The earnings call reveals strong financial performance with increased guidance, new product launches, and strategic growth drivers. Despite slight margin declines and cash flow reduction, the company has managed debt well and engaged in stock repurchases. The Q&A highlights positive sentiment towards AI and robotics integration, and a favorable buying environment in hospitals. The reaffirmed guidance and strategic focus on innovative platforms suggest a positive outlook, likely resulting in a 2% to 8% stock price increase given the market cap.
Omnicell, Inc. (OMCL) Q2 2025 Earnings Conference Call Transcript
Positive8-1
The earnings call highlights strong financial metrics, a positive outlook on product development, and strategic market positioning. Despite concerns about tariffs and Medicaid cuts, the company is mitigating risks through supply chain resiliency and innovative solutions. Guidance remains optimistic, particularly with the potential growth of OmniSphere and IV compounding products. The market cap indicates a more pronounced reaction, suggesting a positive stock movement in the short term.
Earnings call transcript: Omnicell Q1 2025 beats EPS forecasts, stock drops
Unknown5-6
The earnings call reveals several concerns: a significant tariff impact on financial projections, a reduction in EBITDA and EPS guidance, and declining margins. Despite strong revenue growth and strategic product development, the reduction in guidance due to tariffs and uncertainties in supply chain adjustments weigh negatively. The Q&A indicates management's evasiveness on key issues, adding to the market's uncertainty. Given the company's small market cap, the stock may react more strongly to these negative factors, leading to a likely decline in stock price over the next two weeks.
OMCL Slides
Omnicell Q4 2025 slides: EPS miss drives 15% stock drop despite revenue growth2026-02-05
Omnicell Q3 2025 slides: Medication management leader beats estimates, accelerates SaaS growth2025-10-30
Omnicell Q2 2025 slides: Revenue up 5%, shares jump on recurring revenue growth2025-07-31
Omnicell Q1 2025 slides: revenue up 10%, recurring revenue reaches 56% of total2025-05-06
OMCL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
